Welcome

Opportunities in the Neurogenomics Market

 

  • Research Code : 5407-01-00-00-00
  • SKU : HC00227-GL-MR_03185
  • Share this :
  • Release Date : 05-Nov-1998
  • Region : Global
  • Request Study Sample

Availability: In stock

 

Regular Price: USD 3,950

Special Price USD 2,765

30% OFF

* Required Fields

Regular Price: USD 3,950

Special Price USD 2,765

Pay By Invoice

Be the first to review this product



Table of Contents

Opportunities in the Neurogenomics Market, Executive Summary

Valuations of The Genomics Enterprise

Valuations of The Genomics Enterprise

Summary of Major Findings in Each Therapeutic Class

Alzheimer's Disease
Parkinson's Disease
Multiple Sclerosis
Epilepsy
Migraine
Obesity
Major Depression
Schizophrenia

Conclusions

Conclusions

Opportunities in the Neurogenomics Market, Research Methodology; Industry Challenges and Opportunities

Scope and Research Methodology

Scope and Research Methodology

Identification of Challenges and Opportunities Facing Neurogenomics

Identification of Challenges and Opportunities Facing Neurogenomics

Challenges and Opportunities Affecting the Emerging Market for Neurogenomics

Challenges and Opportunities Affecting the Emerging Market for Neurogenomics
Industry Challenges: Neurogenomics
Industry Opportunities: Neurogenomics

Opportunities in the Neurogenomics Market, Market Engineering Research for Neurogenomics

Overview of the Neurogenomics Landscape

The Neurogenomics Enterprise
Scope and Definition of Neurogenomics
Assessment of the Current State of Neurogenomics
Market Opportunity Analysis
Examples of Market Models for Several Existing Alzheimer's Genomic Targets
Competitive Structure

Opportunities in the Neurogenomics Market, Strategic Evaluation of the Neurogenomics Landscape

The Net Present Value (NPV) Approach for Quantifying Market Opportunities

The Net Present Value (NPV) Approach for Quantifying Market Opportunities

The Present Value of Future Therapeutics Opportunities in Neurogenomics

The Present Value of Future Therapeutics Opportunities in Neurogenomics

NPV Analysis of the Entire Neurogenomics Space

NPV Analysis of the Entire Neurogenomics Space

A Closer Look at the NPV for the Migraines Space with Varying Timelines and Discount Rates

A Closer Look at the NPV for the Migraines Space with Varying Timelines and Discount Rates

Opportunities in the Neurogenomics Market, Profiles of Selected Neurogenes

Overview

Overview

Alzheimer Disease 3 (AD3)

Alzheimer Disease 3 (AD3)

Alzheimer Disease 4 (AD4)

Alzheimer Disease 4 (AD4)

Amyloid Precursor Protein (APP)

Amyloid Precursor Protein (APP)

Apolipoprotein E (ApoE)

Apolipoprotein E (ApoE)

PLCD1

PLCD1

alpha-2-macroglobin (A2M)

alpha-2-macroglobin (A2M)

Obese (ob)/Leptin (LEP)

Obese (ob)/Leptin (LEP)

Agouti Related Transcript (ART)

Agouti Related Transcript (ART)

Uncoupling Protein 2 (UCP 2)

Uncoupling Protein 2 (UCP 2)

Cholecystokinin Receptor (CCKBR)

Cholecystokinin Receptor (CCKBR)

Neuropeptide Y (NPY)

Neuropeptide Y (NPY)

Pro-Melanin-Concentrating Hormone (PMCH) Gene

Pro-Melanin-Concentrating Hormone (PMCH) Gene

Calcium Channel; Voltage-Dependent; P/Q type; alpha 1A subunit (CACNL1A4)

Calcium Channel; Voltage-Dependent; P/Q type; alpha 1A subunit (CACNL1A4)

Synuclein; alpha (SNCA)

Synuclein; alpha (SNCA)

Parkin

Parkin

Serotonin Transporter Gene (SLC6A4)

Serotonin Transporter Gene (SLC6A4)

Cholinergic Receptor; Nicotinic; Alpha Polypeptide 4 (CHRNA4)

Cholinergic Receptor; Nicotinic; Alpha Polypeptide 4 (CHRNA4)

Cystatin B (CSTB)

Cystatin B (CSTB)

mtDNA tRNA-lys Mutation

mtDNA tRNA-lys Mutation

Epilepsy; Progressive with Mental Retardation (EPMR)

Epilepsy; Progressive with Mental Retardation (EPMR)

Epilepsy; Juvenile Myoclonic 1 (EJM1)

Epilepsy; Juvenile Myoclonic 1 (EJM1)

Electroencephalographic Variant Pattern 1 (EEGV1)

Electroencephalographic Variant Pattern 1 (EEGV1)

Epilepsy; Generalized; Idiopathic (EGI)

Epilepsy; Generalized; Idiopathic (EGI)

Potassium Channel; Voltage-Gated; Subfamily Q; Member 2 (KCNQ2)

Potassium Channel; Voltage-Gated; Subfamily Q; Member 2 (KCNQ2)

Epilepsy; Benign Neonatal 2 (EBN2 or KCNQ3)

Epilepsy; Benign Neonatal 2 (EBN2 or KCNQ3)

Neurotrophin-3 (NT-3)

Neurotrophin-3 (NT-3)

Opportunities in the Neurogenomics Market, Profiles of Strategically Targeted Companies

Profiles of Strategically Targeted Companies

Profiles of Strategically Targeted Companies

Opportunities in the Neurogenomics Market, Database of Key Industry Participants

Market Participants (Genomics Firms)

Market Participants (Genomics Firms)

Related Companies (Pharmaceutical)

Related Companies (Pharmaceutical)


Sample Study






Related Research
WHY CHOOSE
FROST & SULLIVAN
RESEARCH ?

1. Primary Research

Our analysis is based on comprehensive primary research conducted with core market participants.

2. Global Coverage

Unparalleled coverage of geographies, our analyst & consultant teams are based in 42+ offices spanning the globe.

3. Breadth of Vertical Industries

We cover the broadest spectrum of markets to provide our clients with the most relevant analysis and transformational insights.

4. Visionary Innovation Research

With on-going transformational shifts, our visionary innovation research prepares you with information on key megatrends shaping the future of your industry.

5. Mega Trends

Mega Trends are global forces that transform business, societies and economies.

6. Convergence Research Coverage

Taking an approach of analysing a macro-to-micro impact, our convergence research helps you prepare against an impending 'Kodak moment'.